Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).

Saved in:
Bibliographic Details
Title: Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial).
Authors: Rauber C; Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxication, University Hospital Heidelberg, Heidelberg, Germany conrad.rauber@med.uni-heidelberg.de.; Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany., Roberti MP; Clinical Cooperation Unit Applied Tumor Immunity, DKFZ, Heidelberg, Germany.; Department of Medical Oncology and Internal Medicine VI, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.; NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, NCT, Heidelberg, Germany., Vehreschild MJ; Department of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt, Department of Internal Medicine, Frankfurt, Germany.; Partner Site Bonn-Cologne, German Center for Infection Research (DZIF), Cologne, Germany.; Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany., Tsakmaklis A; Department I of Internal Medicine, University of Cologne, Cologne, Germany.; German Center for Infection Research, Cologne, Germany., Springfeld C; Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.; Department of Medical Oncology and Internal Medicine VI, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.; NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, NCT, Heidelberg, Germany., Teufel A; Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.; Department of Medicine II, Heidelberg University Medical Faculty Mannheim, Mannheim, Germany., Ettrich T; Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany., Jochheim L; Department of Gastroenterology, Hepatology and Transplant Medicine, University of Duisburg-Essen, Duisburg, Germany., Kandulski A; Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology, and Infectious Diseases, University Hospital Regensburg, Regensburg, Germany., Missios P; Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany., Mohr R; Department of Hepatology and Gastroenterology, Charité - UniversitätsmedizinBerlin, Campus Virchow Klinikum (CVK) and Campus Charité Mitte (CCM), Charite Universitatsmedizin Berlin, Berlin, Germany., Reichart A; Department of Gastroenterology, University Hospital Augsburg, Augsburg, Germany., Waldschmidt DT; Department for Gastroenterology and Hepatology, University Hospital Cologne, Cologne, Germany., Sauer LD; Institute of Medical Biometry (IMBI), Heidelberg University, Heidelberg, Germany., Sander A; Institute of Medical Biometry (IMBI), Heidelberg University, Heidelberg, Germany., Schirmacher P; Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany., Jäger D; Clinical Cooperation Unit Applied Tumor Immunity, DKFZ, Heidelberg, Germany.; Department of Medical Oncology and Internal Medicine VI, Medical Faculty Heidelberg, University Hospital Heidelberg, Heidelberg, Germany.; NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, NCT, Heidelberg, Germany., Michl P; Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxication, University Hospital Heidelberg, Heidelberg, Germany.; Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany., Dill MT; Department of Gastroenterology, Hepatology, Infectious Diseases and Intoxication, University Hospital Heidelberg, Heidelberg, Germany.; Liver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.; NCT Heidelberg, a partnership between DKFZ and Heidelberg University Hospital, NCT, Heidelberg, Germany.; Research Group Experimental Hepatology, Inflammation and Cancer, DKFZ, Heidelberg, Germany.
Source: BMJ open [BMJ Open] 2025 Sep 09; Vol. 15 (9), pp. e097802. Date of Electronic Publication: 2025 Sep 09.
Publication Type: Journal Article; Clinical Trial Protocol
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2044-6055
DOI:10.1136/bmjopen-2024-097802